Novartis Drops Entresto Drug Patent Dispute With Crystal Pharma

Novartis Pharmaceuticals Corp.‘s patent infringement dispute with Crystal Pharmaceutical Co. over the blockbuster Entresto heart failure medication was dismissed by a Delaware federal judge on Monday.

• Crystal submitted an Abbreviated New Drug Application to the Food and Drug Administration to approve a generic version of Entresto. Novartis sued Crystal over three patents last year, and Crystal filed counterclaims seeking invalidity and non-infringement.
• Novartis moved to dismiss its own suit and the counterclaims, arguing that a section under Crystal’s application shows that it is no longer seeking FDA approval of any method covered the by the patents.
• Judge Richard G. ...